Topic Discussions: Auto antibodies in diffuse podocytopathies

Recent advances have reshaped how we view nephrotic syndrome moving from descriptive pathology to a mechanism-based model. A growing body of evidence shows that circulating autoantibodies against key slit diaphragm proteins—nephrin, podocin, and Kirrel1—play a central role in many cases of autoimmune podocytopathy. This was also confirmed in pediatric literature. 

These discoveries promise earlier, less invasive diagnosis and more precise, personalized treatment.

Yet, translating these insights into clinical practice is far from straightforward. The antibodies are often present at very low or transient levels, disappearing into the urine during active disease. Their titers fluctuate with relapses and remissions, complicating the timing of tests. Moreover, NS is heterogeneous: while many patients have anti-nephrin antibodies, others harbor antibodies to podocin or Kirrel1, and some exhibit overlapping profiles through “epitope spreading.”

Technical challenges also hamper detection. Assay performance depends on antigen fragment choice, expression system, and protein modifications—especially for the heavily glycosylated nephrin. To improve reliability, researchers emphasize combined strategies, pairing ELISA with high-resolution biopsy techniques like super-resolution microscopy.

The article proposes a roadmap: develop multiplex assays, standardize antigen design, integrate biopsy validation, and pursue longitudinal studies. Success could enable precision diagnostics and tailored therapy, transforming care for children and adults with nephrotic syndrome.

Is it time for targeted therapies for Glomerular Diseases?

IgA Nephropathy and Minimal Change Disease?- a potential association

IgA nephropathy can take many variants. Classically, it can present as the nephritic syndrome but can be just benign hematuria with no other complaints. Sometimes it can be aggressive with crescents and or TMA.  Proteinuria usually suggest a bad prognostic marker in IgA nephropathy.  Sudden onset proteinuria might suggest a dual glomerular process or IgA nephropathy with a minimal change disease variant.  A recent series of cases have been described in CJASN.  A retrospective review of pathology cases in the Columbia Univ path database revealed 17 such cases.  Most had normal creatinine, proteinuria was over 8g for average and biopsy showed co dominant IgA with mesangial deposits and MCD.  14/17 patients got complete remission with steroids and additional agents.

Another case presented in this case report.

KDIGO Guidelines for Glomerular Diseases 2012: Minimal Change Disease

KDIGO Kidney International supplementary material released the guidelines for management of glomerular diseases. ( image source: http://library.med.utah.edu/WebPath/RENAHTML/RENAL102.html)

Topic: Minimal change disease in Adults

1. Initial treatment - Steroids ( Grade 1C) 1mg/kg or alternating 2mg/kg QOD for 4 weeks minimum if complete remission achieved and 16weeks if complete remission not achieved (2C)
2. Taper after remission over 6 months( Grade 2D)
3. If cannot tolerate steroids, oral cyclophosphamide or CNIs can be used( Grade 2D)
4. For relapses, use the same steroid protocols
5. For frequently relapsing and or steroid dependent minimal change, oral cylcophosphamide can be used at 2-2.5mg/kg.day  for 8 weeks( 2C)
6. For frequently relapsing and or steroid dependent minimal change, oral cyclosporine can be used at 3-5mg/kg.day or tacrolimus 0.05-0.1mg/kg/day in divided doses for 1-2 years (2C)
7. MMF 500-1000mg BID for 1-2 years for intolerance also to 5,6 ( 2D)
8. Re-evaluate patients with resistant minimal changes for secondary causes.
9. For initial episode of nephrotic syndrome associated with MCD, statins and ACEI/ARBS not be used in normotensive individuals for proteinuria ( 2D).
10. MCD with AKI, treat with renal repalcement therapy if need be but with steroids.

take a look at full recommendations at http://www.nature.com/kisup/journal/v2/n2/pdf/kisup201218a.pdf